bluebird bio, Inc. (BLUE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Investors who purchased bluebird securities are encouraged to obtain additional information and assist the investigation.           

The investigation concerns whether bluebird has violated federal securities laws.

On March 29, 2023, bluebird announced its financial results for 2022.  Among other items, bluebird indicated a potential delay for its Biologics License Application (“BLA”) for its sickle cell disease candidate lovo-cel, stating that “[i]n early March, the Company responded to feedback from the FDA on vector and drug product analytical comparability evaluations completed in December 2022; bluebird expects a response from the FDA within a matter of weeks and will move quickly to expedite its BLA submission, pending alignment with FDA on product comparability.”  On this news, bluebird’s stock price fell $1.06 per share, or 24.54%, to close at $3.26 per share on March 29, 2023.

If you are aware of any facts relating to this investigation or purchased bluebird shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.